Results 201 to 210 of about 13,036 (257)

Integrated Engineering of CAR‐T Cells for Solid Tumours

open access: yesCell Proliferation, EarlyView.
Solid tumours pose multifactorial barriers including antigen heterogeneity, immunosuppressive microenvironment, and poor T‐cell trafficking, limiting CAR‐T efficacy compared to hematologic malignancies. Integrated engineering strategies are essential, combining logic‐gated receptors for precision, metabolic‐epigenetic reprogramming for resilience, and ...
Chao Yang   +5 more
wiley   +1 more source

Beyond interferon gamma - decreased cellular response to COVID-19 vaccination booster in patients with autoimmune inflammatory rheumatic diseases. [PDF]

open access: yesFront Immunol
Wroński J   +9 more
europepmc   +1 more source

Granzymes in cancer and immunity [PDF]

open access: yesCell Death and Differentiation, 2010
Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are indispensable factors in the body's ongoing defence against viral infection and tumor development. CTL/NK cells recognize and kill infected or aberrant target cells by two major pathways: either through introduction of a battery of proteases - called granzymes - to the target cell cytosol,
Seamus Martin, Martin S J
exaly   +3 more sources

A quarter century of granzymes [PDF]

open access: yesCell Death and Differentiation, 2011
Granzymes (Grs) were discovered just over a quarter century ago. They are produced by cytotoxic T cells and natural killer cells and are released upon interaction with target cells. Intensive biochemical, genetic, and biological studies have been performed in order to study their roles in immunity and inflammation.
Bleackley R C, Kane K P, R C Bleackley
exaly   +3 more sources

Granzymes—Their Role in Colorectal Cancer

open access: yesInternational Journal of Molecular Sciences, 2022
Colorectal cancer (CRC) is among the most common malignancies worldwide. CRC is considered a heterogeneous disease due to various clinical symptoms, biological behaviours, and a variety of mutations. A number of studies demonstrate that as many as 50% of CRC patients have distant metastases at the time of diagnosis.
Marta Łukaszewicz-Zając   +2 more
exaly   +3 more sources

Home - About - Disclaimer - Privacy